Drupal.behaviors.print = function(context) {window.print();window.close();}>
Epizyme Publishes Data Suggesting Compound Activity against Lymphoma with EZH2 Mutations
October 03, 2012
Epizyme Publishes Data Suggesting Compound Activity against Lymphoma with EZH2 Mutations
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Epizyme Taps Roche to Develop Cobas 4800 CDx for Epizyme/Eisai Lymphoma Drug Candidate
January 10, 2013 / PCR Insider
MDx/CDx Focus: Abbott, Epizyme Advance CDx for Novel Leukemia Drug; Segeene, Selventa Develop MDx
April 24, 2013 / Pharmacogenomics Reporter
Abbott to Develop Companion Dx for Epizyme Cancer Drug Candidate
April 18, 2013 / GenomeWeb Daily News
Insight Genetics to Participate in NCI's Program to Move Assays to Clinical Trials
April 3, 2013 / GenomeWeb Daily News
Epizyme, Eisai, Roche Partner to Develop CDx for Investigational Lymphoma Treatment
January 7, 2013 / GenomeWeb Daily News